Second Sight Medical Products Inc(NASDAQ:EYES) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Jul 28, 2016. Company reported revenue of $1.04M. Analysts estimated a revenue of $1.38M. Earnings per share were $-0.17. Analysts had estimated an EPS of $-0.15.
Second Sight Medical Products Inc (EYES) shares turned negative on Thursdays trading session with the shares closing down -0.07 points or -1.75% at a volume of 1,19,977. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $4.06. The peak price level was also seen at $4.06 while the days lowest was $3.92. Finally the shares closed at $3.93. The 52-week high of the shares is $14.95 while the 52-week low is $3.17. According to the latest information available, the market cap of the company is $142 M.
Several Insider Transactions has been reported to the SEC. On Jun 7, 2016, Edward David Randolph (VP of Manufacturing) sold 5,104 shares at $4.01 per share price.Also, On Jun 6, 2016, Robert J. Greenberg (Chairman of Board) sold 8,571 shares at $4.10 per share price.On Dec 7, 2015, Anne-marie Juliette Ripley (VP of Regulatory Affairs) sold 2,500 shares at $5.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Second Sight Medical Products Inc. is a medical device company that develops manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product the Argus II System treats outer retinal degenerations such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision that normally sighted people have. The Argus II Retinal Prosthesis System consists of an implant a small portable computer and a pair of glasses with a miniature video camera. The Argus II system received Conformite Europeenne (CE) Mark approval for marketing and sales in the European Union (EU) and approval by the United States Food and Drug Administration (FDA) for marketing and sales in the United State. The Company also markets the Argus II system in Canada Turkey and at one medical center in Saudi Arabia.